Research
Faculty Research Initiatives — Clinical Trials
« Back to Faculty Research Initiatives page
| Protocol No.: |
8029 (NCI Contract N01-CM-27165) |
| Principal Investigator: |
Karen A. Kurdziel, M.D. |
| Title: |
A Phase 2 Study of 3’-Deoxy-3’-18F Fluorothymidine in Invasive Breast Cancer |
| Sponsor: |
National Cancer Institute and National Institutes of Health |
| Disease State: |
Breast cancer |
| Drug/Agent: |
18F Fluorothymidine and 18F Fluorodeoxyglucose |
| Imaging/Procedure: |
Positron Emission Tomography imaging at three time points during chemotherapy course |
| Status: |
Open |
| Contact: |
Kristin Schmidt, (804) 828-4178, kschmidt@vcu.edu |
| Protocol No.: |
ACRIN-6678 |
| Principal Investigator: |
Robert A. Halvorsen, Jr., M.D. |
| Title: |
FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-small Cell Lung Cancer |
| Sponsor: |
American College of Radiology Imaging Network |
| Location: |
National, multi-center |
| Disease State: |
Non-small cell lung cancer, Stage IIIB or IV |
| Drug/Agent: |
18F Fluorodeoxyglucose |
| Imaging/Procedure: |
Positron Emission Tomography imaging at three time points during chemotherapy course |
| Status: |
Open |
| Contact: |
Kristin Schmidt, (804) 828-4178, kschmidt@vcu.edu
www.acrin.org |
| Protocol No.: |
1 R21 CA130345-01 |
| Principal Investigator: |
Karen A. Kurdziel, M.D. |
| Title: |
Phase 1 Evaluation of F-18 Paclitaxel (FPAC) as a Potential In Vivo Marker of Multidrug Resistance in Breast and Lung Cancer |
| Sponsor: |
National Cancer Institute and National Institutes of Health |
| Disease State: |
Breast cancer, Non-small cell lung cancer |
| Drug/Agent: |
18F Fluoropaclitaxel (FPAC) |
| Imaging/Procedure: |
Positron Emission Tomography (PET) |
| Status: |
Pending |
| Contact: |
Kristin Schmidt, (804) 828-4178, kschmidt@vcu.edu |
| Protocol No.: |
EDCCTA-0601 |
| Principal Investigator: |
John D. Grizzard, M.D., and Michael C. Kontos, M.D. (Cardiology) |
| Title: |
Utility of 64-slice Multidetector CT Coronary Angiography in the Evaluation of Low- and Intermediate-risk Chest Pain Patients |
| Disease State: |
Chest pain, acute coronary syndromes |
| Drug/Agent: |
Isovue-370™ |
| Imaging/Procedure: |
Coronary CT Angiography |
| Status: |
Open |
| Contact: |
Kristin Schmidt, (804) 828-4178, kschmidt@vcu.edu |
| Protocol No.: |
VCU 4471 |
| Principal Investigator: |
Birgit Kettenmann, Ph.D. |
| Title: |
Orbitofrontal Cortex Activity Measured by fMRI in Relation to Perception of Food Odors in Obese Patients: Feedback Mechanisms Controlling Food Intake |
| Disease State: |
Obesity; normal volunteers |
| Imaging/Procedure: |
Functional MRI of brain before and after eating |
| Status: |
Open |
| Contact: |
Kristin Schmidt, (804) 828-4178, kschmidt@vcu.edu |
| Protocol No.: |
P-2611 |
| Principal Investigator: |
Daniel A. Leung, M.D. |
| Title: |
Carotid Revascularization with ev3 Arterial Technology Evolution Post Approval Study |
| Sponsor: |
ev3 Inc. |
| Location: |
National, multi-center |
| Device: |
PROTÉGÉ® RX Stent & SpiderFX™ Embolic Protection Device |
| Status: |
Open |
| Contact: |
Megan Quinn, (804) 828-8196, mmquinn@vcu.edu |
| Protocol No.: |
ACRIN 6664 |
| Principal Investigator: |
Robert A. Halvorsen, Jr. M.D. |
| Title: |
National CT Colonography Trial |
| Sponsor: |
American College of Radiology Imaging Network |
| Location: |
National, multi-center |
| Imaging/Procedure: |
CTC uses virtual reality technology to produce two- and three-dimensional images that permit a thorough and minimally invasive evaluation of the entire colon. The study requires no sedation, and takes approximately 10 to 20 minutes. |
| Status: |
Closed |
| Contact: |
www.acrin.org |
| Protocol No.: |
MCC 03748 |
| Principal Investigator: |
Karen A. Kurdziel, M.D. |
| Title: |
Pilot Study of 18F Fluoropaclitaxel in Breast Cancer Patients and Normal Volunteers: Dosimetry, Safety and Feasibility |
| Disease State: |
Breast cancer, healthy volunteers |
| Drug/Agent: |
18F Fluoropaclitaxel (FPAC) |
| Imaging/Procedure: |
Positron Emission Tomography |
| Status: |
Closed |
| Protocol No.: |
RG1068-15-02 |
| Principal Investigator: |
Ann S. Fulcher, M.D. |
| Title: |
A Phase II Study to Assess the Safety and Methods for Determining the Efficacy of RG1068 (Synthetic Human Secretin): Enhanced Magnetic Resonance Cholangiopancreatography in the Evaluation of Patients with a History of Pancreatic Abnormalities |
| Sponsor: |
Repligen |
| Location: |
National, multi-center |
| Drug/Agent: |
RG1068 (Synthetic Human Secretin) |
| Imaging/Procedure: |
Magnetic Resonance Cholangiopancreatography |
| Status: |
Closed |
